Rare Disease Protein Revealed as Key Enzyme in Cellular Lipid Recycling

A long-standing mystery at the heart of a devastating childhood neurodegenerative disorder has finally begun to yield its secrets. In a study published in Nature Cell Biology, researchers report that CLN8, a protein whose defects cause a form of Batten disease, functions as a stereospecific acyltransferase in the biosynthesis of bis(monoacylglycero)phosphate, an unusual lysosomal lipid that is essential for normal cellular housekeeping. The finding transforms CLN8 from a poorly characterized membrane protein into a defined enzyme with a measurable biochemical activity, and it offers researchers a concrete molecular handle on a disease that has, for decades, resisted mechanistic explanation.

Batten disease, also known as neuronal ceroid lipofuscinosis, refers to a family of inherited disorders in which waste materials accumulate inside lysosomes, the recycling compartments of the cell. The resulting buildup, particularly in neurons, leads to progressive vision loss, seizures, motor decline, and early death. More than a dozen genes have been linked to different forms of the disease, yet for many of the encoded proteins, including CLN8, the normal function has remained frustratingly vague. CLN8 was known to sit in the endoplasmic reticulum and to travel along an ER-to-Golgi recycling pathway, but what it actually did during those journeys was unclear.

The new work answers that question with striking specificity. Two independent lines of investigation converged on the same conclusion: CLN8 catalyzes the acyl-CoA-dependent acylation of glycerophosphoglycerol, a small phosphorylated glycerol backbone, to produce lysophosphatidylglycerol. That reaction is the committed first step in a pathway that ultimately generates bis(monoacylglycero)phosphate, or BMP, a lipid so structurally peculiar that it is found almost exclusively in late endosomes and lysosomes, where it makes up a substantial fraction of the internal membrane surfaces.

The stereochemical detail matters. BMP is one of the very few lipids in mammalian cells with an unusual sn-1:sn-1′ glycerophosphate configuration, the mirror image of the configuration found in nearly every other glycerophospholipid. Because standard phospholipases cannot easily degrade this reversed architecture, BMP is intrinsically resistant to breakdown, an ideal property for a lipid that must persist in the harsh, enzyme-dense interior of the lysosome. Demonstrating that CLN8 is a stereospecific acyltransferase means the protein does not merely participate vaguely in lipid traffic; it selects the correct substrate, transfers the correct fatty acid chain from acyl-CoA, and initiates the construction of this biologically distinctive molecule.

Why should the failure to make BMP cause a brain disease? The answer lies in the lysosome’s operating principles. Lysosomes degrade cellular debris, damaged organelles, and macromolecules through the action of acid hydrolases, and many of those hydrolases require a membrane environment that can accept and present lipidated cargo. BMP is indispensable for the formation of intraluminal vesicles within multivesicular bodies, the structures in which lipid and protein cargo are delivered to degradative enzymes. Without adequate BMP, the sorting and degradation of cargo falters, and undigested material begins to pile up, precisely the hallmark pathology of Batten disease.

The experimental logic behind the discovery illustrates the power of modern lipid biochemistry combined with genetics. Rather than inferring function from protein interactions or localization alone, the researchers directly tested whether CLN8-containing preparations could convert glycerophosphoglycerol into lysophosphatidylglycerol in an acyl-CoA-dependent manner. The activity tracked with CLN8, was lost when CLN8 was removed or inactivated, and was restored when functional CLN8 was reintroduced. Disease-associated mutations in the protein compromised the enzymatic output, tying the biochemistry directly to the clinical syndrome. Complementary studies reached the same enzymatic assignment from different starting points, giving the conclusion unusual robustness.

Placing CLN8 in the pathway also resolves a long-standing gap. Scientists had identified downstream enzymatic steps that convert lysophosphatidylglycerol into BMP, and they knew where BMP accumulated, but the enzyme that supplies the pathway’s first committed product had been elusive. Identifying CLN8 as the acyltransferase means the biosynthetic route from a simple glycerophosphate precursor to the lysosome’s signature lipid is now, in outline, complete. It also explains previous observations that cells lacking CLN8 show abnormalities in lysosomal lipid composition and in the morphology of late endocytic compartments.

There are broader implications for membrane biology as well. CLN8 belongs to a family of ER-associated proteins, several of which have been linked to lysosomal storage diseases, that shuttle between the endoplasmic reticulum and the Golgi apparatus. If CLN8 performs its acyltransferase function at the ER or in transit, lipid synthesis may be spatially coupled to the trafficking routes that supply the endolysosomal system. That would suggest a model in which the cell builds a degradative lipid at its manufacturing hub and ships it forward, with CLN8 acting both as enzyme and possibly as escort. Testing that model will be a central task for future work.

For patients and families, the discovery does not translate immediately into therapy, but it changes the landscape of what therapy could look like. If the primary defect in CLN8 disease is a shortfall of BMP, then interventions that restore BMP levels, supply downstream lipid intermediates, or enhance parallel pathways for lysosomal membrane remodeling become plausible strategies. Enzyme replacement is complicated by the fact that CLN8 is an integral membrane protein embedded in intracellular membranes, a notoriously difficult class of therapeutic target. Small molecules that boost residual CLN8 activity, chaperone misfolded variants, or bypass the blocked step chemically are the kinds of approaches the new mechanistic understanding now makes testable.

The study also adds momentum to a growing realization that many so-called storage diseases are, at their core, diseases of lipid metabolism. As genome-encoded enzymes of lipid synthesis and remodeling continue to be matched with the disorders that arise when they fail, the field moves closer to a unified map connecting genes, membranes, and cellular decline. For CLN8, the journey from a disease gene of unknown purpose to a defined stereospecific acyltransferase is a striking example of that progress, and a reminder that even the most opaque proteins eventually surrender their function to patient biochemical scrutiny.

Subject of Research: Enzymatic function of the Batten disease protein CLN8 in bis(monoacylglycero)phosphate lipid biosynthesis

Article Title: The Batten disease protein CLN8 is a stereospecific acyltransferase in bis(monoacylglycero)phosphate biosynthesis

Article References: Sheokand, P. K., Lacabanne, D., James, A. M., Della Vecchia, S., Ruprecht, J. J., van der Kleij, J., Turner, K., Müller-Niva, J., Salo, M. H., Jenkins, B., Leese, S. K., Juneja, N., Yu, C. S., Booth, C. D., King, M. S., Uusimaa, J., Weimer, J. M., Koulman, A., Hinttala, R., … Petkevicius, K. (2026). The Batten disease protein CLN8 is a stereospecific acyltransferase in bis(monoacylglycero)phosphate biosynthesis. Nature Cell Biology. https://doi.org/10.1038/s41556-026-02061-0

Image Credits: AI Generated

DOI: 10.1038/s41556-026-02061-0

Keywords: Batten disease, CLN8, lysosomal storage disorders, bis(monoacylglycero)phosphate, lipid biosynthesis, acyltransferase, endoplasmic reticulum, lysosome, neuronal ceroid lipofuscinosis, lipid metabolism, glycerophosphoglycerol, neurodegeneration